Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11618-11629
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11618
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11618
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways
Rong-Juan Pei, Xin-Wen Chen, Meng-Ji Lu, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, Hubei Province, China
Meng-Ji Lu, Institute of Virology, University Hospital of Essen, 45122 Essen, Germany
Author contributions: All the authors participated in the paper.
Supported by National Natural Science Foundation of China to Pei RJ and Chen XC, Nos. 31200135 and 31200699; German Research Foundation to Lu MG, Nos. TRR60, GK1045/2 and GK1949
Correspondence to: Meng-Ji Lu, Professor, Institute of Virology, University Hospital of Essen, Hufelandstrasse 55, 45122 Essen, Germany. mengji.lu@uni-due.de
Telephone: +49-201-7233530 Fax: +49-201-7235929
Received: November 6, 2013
Revised: February 28, 2014
Accepted: April 15, 2014
Published online: September 7, 2014
Processing time: 306 Days and 22.7 Hours
Revised: February 28, 2014
Accepted: April 15, 2014
Published online: September 7, 2014
Processing time: 306 Days and 22.7 Hours
Core Tip
Core tip: Hepatitis B virus (HBV) infection is one of the major causes of liver diseases affecting more than 350 million people worldwide. Interferon (IFN)- and Toll-like receptors (TLR)-mediated innate immune responses could restrict HBV replication at the different steps of viral life cycle. Though a great number of publications in this field appeared during the last years, there is no review to discuss the progress. Here, we summarized the currently available knowledge about the anti-HBV effect of IFNs and TLRs and the possible effectors downstream the IFN signaling pathway. This review provides an overview for scientists working on HBV and related fields.